BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30639309)

  • 1. Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling.
    Liu N; Guo Z; Xia X; Liao Y; Zhang F; Huang C; Liu Y; Deng X; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Mar; 846():1-11. PubMed ID: 30639309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
    Liu N; Li X; Huang H; Zhao C; Liao S; Yang C; Liu S; Song W; Lu X; Lan X; Chen X; Yi S; Xu L; Jiang L; Zhao C; Dong X; Zhou P; Li S; Wang S; Shi X; Dou PQ; Wang X; Liu J
    Oncotarget; 2014 Jul; 5(14):5453-71. PubMed ID: 24977961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.
    Liao Y; Liu N; Hua X; Cai J; Xia X; Wang X; Huang H; Liu J
    Cell Death Dis; 2017 Feb; 8(2):e2585. PubMed ID: 28151478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artesunate Suppresses the Growth of Prostatic Cancer Cells through Inhibiting Androgen Receptor.
    Wang Z; Wang C; Wu Z; Xue J; Shen B; Zuo W; Wang Z; Wang SL
    Biol Pharm Bull; 2017; 40(4):479-485. PubMed ID: 28381803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens.
    Nunes JJ; Pandey SK; Yadav A; Goel S; Ateeq B
    Neoplasia; 2017 Apr; 19(4):333-345. PubMed ID: 28319807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.
    Mizutani N; Inoue M; Omori Y; Ito H; Tamiya-Koizumi K; Takagi A; Kojima T; Nakamura M; Iwaki S; Nakatochi M; Suzuki M; Nozawa Y; Murate T
    J Biochem; 2015 Oct; 158(4):309-19. PubMed ID: 25888580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
    Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
    J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
    Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
    Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
    Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.